Welcome to our blog! This is where we share a bit more – insights, updates, and thoughts from Genovis. Take a look around and see what you find.
Search post
Category
We are expanding our enzyme platform with a proprietary portfolio of precision proteases for protein analysis! We have entered into an agreement to acquire, and completed the acquisition of, 100 percent of the shares in KPL ApS (“KPL”), a Denmark‑based life science tools company with a proprietary portfolio of precision enzymes (proteases), both commercialized and…
IgMBRAZOR is a unique IgM-specific protease that digests human IgM at one specific site below the CH2 domain in the heavy chain, generating homogeneous F(ab’)2 and Fc fragments. We're excited to launch this unique tool today that enables middle-level analysis of the complex and high molecular weight human IgM! IgMBRAZOR facilitates IgM characterization during,…
Genovis and ArcticZymes are excited to announce a collaboration to speed up penetration and growth in the Chinese market.
Today, Genovis has acquired the patent rights to a unique DNA polymerase developed by researchers at Uppsala University. The enzyme has potential applications in research, diagnostics and forensics.
We have entered a service agreement with evitria AG (Zürich, Switzerland) to offer a fast and high-quality LC-MS characterization of recombinant antibodies using our SmartEnzymes™ workflows!
The new collaboration between Genovis and Waters Corporation is intended to bring fast and easy analytical workflows for biopharmaceuticals by combining the SmartEnzymes™ portfolio from Genovis with the unique instrumentation from Waters™. The lab work has already started, and we got a quick word with Andreas Nägeli, one of the scientists at Genovis contributing to…
Genovis receives funding from Vinnova for the development of a new high-throughput platform for a directed and efficient product development for quality assurance of biological drugs. To understand the project we got a quick word with the VP of Research & Development at Genovis, Rolf Lood. Rolf is heading the enzyme discovery team at Genovis…
Genovis has reached a settlement in its patent infringement lawsuit with Promega Corp. and agreed to a royalty bearing, worldwide license to the patents-in-suit. The settlement ends all ongoing patent-infringement claims between the parties and Promega has agreed to a royalty bearing, worldwide license to the patents-in-suit, thereby ending the lawsuit between the parties. The…
Genovis expands the protease portfolio with GingisREX - a new enzyme with unique specificity for arginine residues. The GingisREX protease can be used for peptide mapping, protein sequencing and post-translational modification analysis using mass spectrometry. Press release Read more about GingisREX
The cooperation agreement will provide Genovis with access to Alphalyse’s expertise in mass spectrometry while Alphalyse will have the opportunity to offer its customers analyses based on Genovis’ unique enzymes for antibodies and other pharmaceutical proteins.
Genovis is launching a further development of GingisKHAN® that will be marketed under the name GingisKHAN®Fab kit. The product will be presented at the conference Antibody Engineering & Therapeutics in San Diego next week.
The Board of Directors of Genovis AB (publ) has decided to publish Q3 2015 report ahead of schedule.